Jefferies analyst Peter Welford upgraded AstraZeneca to Buy from Hold with a price target of $80, up from $66.50. The company’s assets outside oncology “are being largely ignored, offering significant upside optionality,” the analyst tells investors in a research note. The firm says Airsupra is noteworthy as it sees near $1B more sales backed by its U.S. proprietary physician survey. Jefferies also views tozorakimab, Farxiga follow-ons and eplontersen as “blockbuster opportunities.” It believes upcoming clarity on oncology debates should lift the overhang on AstraZeneca shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AZN:
- AstraZeneca call volume above normal and directionally bullish
- AstraZeneca says Dato-DXd showed significant improvement for primary endpoint
- AstraZeneca says Dato-DXd improved PFS in breast cancer trial
- Cantor Fitzgerald biotech analysts to hold an analyst/industry conference call
- Alexion completes gene therapy purchase and license agreement from Pfizer